Article
IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.
Blood - 20 Aug 2026
Bendig Sonja, Hartmann Alina M, Wessels Wiebke, Beder Thomas, Kim Rathana, Passet Marie, Gao Qingsong, Wolgast Nadine, Horns Johanna M, Santos Leonardo Alves, Iben Katharina, Steffen Fabio D, Cantoni Loredana, Kehden Britta, Chitadze Guranda, Künstner Axel, Busch Hauke, Bornhauser Beat, Bourquin Jean-Pierre, Leguay Thibaut, Boissel Nicolas, Gökbuget Nicola, Iacobucci Ilaria, Mullighan Charles G, Clappier Emmanuelle, Baldus Claudia D, Brüggemann Monika, Bastian Lorenz
Abstract excerpt
ABSTRACT: Large-scale sequencing efforts have defined up to 27 diagnostic subtypes in B-cell precursor acute lymphoblastic leukemia (B-ALL), leaving few samples unclassified. Extended genomic and transcriptomic profiling in routine diagnostics broadens the sample collection, enabling identification of novel subtypes. We analyzed 4857 patients with B-ALL from 3 cohorts and identified a group of 20 patients (age,...
Topics
Join the communities discussing this publication.
